1133386-93-2

1133386-93-2 structure

Name: Alfuzosin-d7
Chemical Name: Alfuzosin-d7
CAS Number: 1133386-93-2
Molecular Formula: C₁₉H₂₀D₇N₅O₄
Molecular Weight: 396.49
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2023-06-20 13:21:52
Modify Date: 2024-04-09 12:21:10
Alfuzosin-d7 is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

Name	Alfuzosin-d7

Description	Alfuzosin-d7 is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63(3):169-76. [3]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar45(3):410-29.

Molecular Formula	C₁₉H₂₀D₇N₅O₄
Molecular Weight	396.49